Effect of inhibition of the lysophosphatidic acid receptor 1 on metastasis and metastatic dormancy in breast cancer.

J Natl Cancer Inst 2012 Sep 21;104(17):1306-19. Epub 2012 Aug 21.

The Women's Cancers Section, Laboratory of Molecular Pharmacology, Center for Cancer Research, National Institutes of Health, Bethesda, MD 20892, USA.

Background: Previous studies identified the human nonmetastatic gene 23 (NME1, hereafter Nm23-H1) as the first metastasis suppressor gene. An inverse relationship between Nm23-H1 and expression of lysophosphatidic acid receptor 1 gene (LPAR1, also known as EDG2 or hereafter LPA1) has also been reported. However, the effects of LPA1 inhibition on primary tumor size, metastasis, and metastatic dormancy have not been investigated.

Methods: The LPA1 inhibitor Debio-0719 or LPA1 short hairpinned RNA (shRNA) was used. Primary tumor size and metastasis were investigated using the 4T1 spontaneous metastasis mouse model and the MDA-MB-231T experimental metastasis mouse model (n = 13 mice per group). Proliferation and p38 intracellular signaling in tumors and cell lines were determined by immunohistochemistry and western blot to investigate the effects of LPA1 inhibition on metastatic dormancy. An analysis of variance-based two-tailed t test was used to determine a statistically significant difference between treatment groups.

Results: In the 4T1 spontaneous metastasis mouse model, Debio-0719 inhibited the metastasis of 4T1 cells to the liver (mean = 25.2 liver metastases per histologic section for vehicle-treated mice vs 6.8 for Debio-0719-treated mice, 73.0% reduction, P < .001) and lungs (mean = 6.37 lesions per histologic section for vehicle-treated mice vs 0.73 for Debio-0719-treated mice, 88.5% reduction, P < .001), with no effect on primary tumor size. Similar results were observed using the MDA-MB-231T experimental pulmonary metastasis mouse model. LPA1 shRNA also inhibited metastasis but did not affect primary tumor size. In 4T1 metastases, but not primary tumors, expression of the proliferative markers Ki67 and pErk was reduced by Debio-0719, and phosphorylation of the p38 stress kinase was increased, indicative of metastatic dormancy.

Conclusion: The data identify Debio-0719 as a drug candidate with metastasis suppressor activity, inducing dormancy at secondary tumor sites.

Download full-text PDF

Source
http://dx.doi.org/10.1093/jnci/djs319DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3611817PMC
September 2012
32 Reads

Publication Analysis

Top Keywords

metastasis mouse
16
tumor size
16
primary tumor
16
mouse model
16
metastatic dormancy
12
metastasis
11
size metastasis
8
4t1 spontaneous
8
debio-0719-treated mice
8
lpa1 inhibition
8
effects lpa1
8
acid receptor
8
reduction 001
8
spontaneous metastasis
8
inhibited metastasis
8
histologic vehicle-treated
8
lysophosphatidic acid
8
metastasis metastatic
8
mda-mb-231t experimental
8
vehicle-treated mice
8

Similar Publications